Current Research Projects
Mesothelioma UK values patient participation in our research. If you are interested in contributing to any of our open studies, please call our Freephone Information Line on 0800 169 2409 or email firstname.lastname@example.org to enquire about current opportunities.
Exploring Clinical Decision Making in Mesothelioma Treatment Pathways across three NHS Trusts: Mixed Methods Study
This grant was awarded in 2018 in partnership with Lung Cancer Nursing UK. The recipient of the grant was Dr Catherine Henshall, Senior Nursing Research Fellow at Oxford Brookes University who previously carried out research funded by Mesothelioma UK into the experiences of follow up care in different trusts.
This study aims to develop a collaborative, evidence-based, patient-centred approach to mesothelioma clinical decision-making across three NHS Trusts: Oxford University Hospitals, Royal Berkshire, and Buckinghamshire NHS Foundation Trusts.
Objectives to be compared across three trusts are:
- Guidelines, policies and processes exist to inform clinical decision-making in relation to mesothelioma treatment pathways, how closely they align and why
- Factors influencing multi-disciplinary team (MDT) decision-making in mesothelioma treatment
- Clinicians’ awareness of/engagement with mesothelioma research and how this informs practice
- Current and potential strategies for improving clinician engagement with mesothelioma research
Understanding the Role of the CNS in Meeting the Palliative Care Needs of Patients and Families: Mixed Methods Study
Dr Clare Gardiner and the team at the Mesothelioma UK Research Centre at Sheffield are studying the palliative care needs of patients with mesothelioma and explore the role of Mesothelioma UK clinical nurse specialists in providing care for patients with mesothelioma and their families.
This study explores the palliative care needs, outcomes, and experiences of patients with mesothelioma and their family carers. It also explores how Mesothelioma UK Clinical Nurse Specialists (CNSs) seek to meet these needs in terms of the interventions they employ, care they provide and the ways they work with other health care providers.
Genomics of Peritoneal Malignancy including rare forms of Mesothelioma
In 2019, Mesothelioma UK granted funding for a collaborative project between the University of Southampton Genomic Informatics Group, a world–recognised expert in cellular pathology with specific expertise in peritoneal malignancy and the Peritoneal Malignancy Institute (PMI), Basingstoke, which is one of the highest volume centres in the world for peritoneal malignancy.
This project aims to characterise peritoneal cancers, with a focus on peritoneal mesotheliomas, to catalogue the key transformative genetic changes driving these tumours. Tumour samples that have been collected and stored by the Peritoneal Malignancy Institute at Basingstoke will be selected for cutting-edge genetic analyses.
The lead researcher is Sarah Ennis, Professor of Genomics at the University of Southampton.
The Experience of Long-Term Survival in People Affected by Pleural Mesothelioma and their Carers
Awarded in partnership with Lung Cancer Nursing UK, Dr Matthew Johnson, in conjunction with the Mesothelioma UK Research Centre at Sheffield will be conducting research into the experience of long-term survivors of mesothelioma.
It aims to gain an in-depth understanding of the experience of living as a long-term survivor with pleural mesothelioma from the perspective of the people diagnosed with the condition and their primary carers.
The specific study objectives are to:
- Gain detailed insight into the practical impact of living with, undergoing treatment for, and coping with symptoms on people with a long-term diagnosis of mesothelioma and their primary carer
- Explore the long-term emotional impact of living with and caring for someone with mesothelioma
- Identify helpful and unhelpful communication during the initial diagnosis that has impacted on subsequent coping with the condition in the longer–term
- Make recommendations on the support needs of people living with long-term mesothelioma and their primary carers
Immunotherapy for Malignant Mesothelioma using IL-6 neutralising CAR-Tcells
Awarded in 2018 in partnership with the British Lung Foundation, Dr John Maher was granted £149,977 to investigate how ‘t-cells’ can be used to treat mesothelioma.
More effective treatments are required for patients with mesothelioma. One approach involves teaching a type of white blood cell, called a ‘T cell’, to recognise and destroy tumour cells. This project aims to move this technology closer to clinical trials by developing a better approach that is likely to have fewer side effects.
The expected end date of this research is July 2021.